158 related articles for article (PubMed ID: 36099437)
1. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
2. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
3. Subclassification of epithelioid sarcoma with potential therapeutic impact.
Haefliger S; Chervova O; Davies C; Nottley S; Hargreaves S; Sumathi VP; Amary F; Tirabosco R; Pillay N; Beck S; Flanagan AM; Lyskjaer I
J Pathol; 2023 Aug; 260(4):368-375. PubMed ID: 37316954
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
5. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
6. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
7. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.
Del Savio E; Maestro R
Cells; 2022 Aug; 11(17):. PubMed ID: 36078034
[TBL] [Abstract][Full Text] [Related]
8. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
9. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
11. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms.
Dermawan JK; Singer S; Tap WD; Nacev BA; Chi P; Wexler LH; Ortiz MV; Gounder M; Antonescu CR
Mod Pathol; 2022 Dec; 35(12):1900-1909. PubMed ID: 36088476
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.
Papp G; Krausz T; Stricker TP; Szendrői M; Sápi Z
Genes Chromosomes Cancer; 2014 Feb; 53(2):168-76. PubMed ID: 24327545
[TBL] [Abstract][Full Text] [Related]
13. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
Modena P; Lualdi E; Facchinetti F; Galli L; Teixeira MR; Pilotti S; Sozzi G
Cancer Res; 2005 May; 65(10):4012-9. PubMed ID: 15899790
[TBL] [Abstract][Full Text] [Related]
14. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma.
Flucke U; Slootweg PJ; Mentzel T; Pauwels P; Hulsebos TJ
Hum Pathol; 2009 Sep; 40(9):1361-2; author reply 1362-4. PubMed ID: 19683621
[No Abstract] [Full Text] [Related]
15. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.
Le Loarer F; Zhang L; Fletcher CD; Ribeiro A; Singer S; Italiano A; Neuville A; Houlier A; Chibon F; Coindre JM; Antonescu CR
Genes Chromosomes Cancer; 2014 Jun; 53(6):475-86. PubMed ID: 24585572
[TBL] [Abstract][Full Text] [Related]
16. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases.
Folpe AL; Schoolmeester JK; McCluggage WG; Sullivan LM; Castagna K; Ahrens WA; Oliva E; Biegel JA; Nielsen GP
Am J Surg Pathol; 2015 Jun; 39(6):836-49. PubMed ID: 25651469
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
19. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions.
Sullivan LM; Folpe AL; Pawel BR; Judkins AR; Biegel JA
Mod Pathol; 2013 Mar; 26(3):385-92. PubMed ID: 23060122
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
